leadf
logo-loader
viewGenedrive PLC

Genedrive PLC - Response to new COVID strain

RNS Number : 4144J
Genedrive PLC
21 December 2020
 

 

genedrive plc

("genedrive" or the "Company")

 

Response to new COVID strain

Genedrive 96 SARS CoV-2 Kit able to detect all published virus strains

 

Genedrive plc (AIM: GDR), the near patient molecular diagnostics company, confirms that its Genedrive 96 SARS CoV-2 Kit continues to detect all known variants of COVID-19, including the newest variants released by the UK's COVID-19 Genomics UK Consortium.

 

The Genedrive 96 SARS-CoV-2 Kit is designed to target both the E and N genes of SARS-CoV-2. The new variant involves a mutation in the highly mutagenic S gene, which encodes spike proteins, and is not one the Company rely on for detection of the virus.

 

David Budd, CEO of genedrive plc said: "We have carried out detailed in silico analysis of 155,276 sequences on the GISAID database. The results show that the test is able to detect all published COVID-19 strains with the same high level of accuracy and demonstrates 100% homology."

 

For further details please contact:

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO




Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson




finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane




Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com)

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RSPKKDBQQBDDOBB

Quick facts: Genedrive PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: FTSE falls and UK inflation up to 0.7% on back of rising food...

FTSE 100 opened in the red after the latest inflation data came in higher than forecasts. London’s leading index lost 14 points to 6,734 in early trading.   UK prices rose 0.7% in the year to January and are expected to jump further as demand increases over the next months. Food and more...

1 week ago

3 min read